Xinjie Lu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10911073/publications.pdf Version: 2024-02-01



YINUE LU

#	Article	IF	CITATIONS
1	Long-Term Efficacy and Safety of Immunomodulatory Therapy for Atherosclerosis. Cardiovascular Drugs and Therapy, 2019, 33, 385-398.	2.6	2
2	Immune regulation by oral tolerance induces alternate activation of macrophages and reduces markers of plaque destabilization in Apobtm2Sgy/Ldlrtm1Her/J mice. Scientific Reports, 2017, 7, 3997.	3.3	12
3	Oral administration of recombinant <i>Mycobacterium smegmatis</i> expressing a tripeptide construct derived from endogenous and microbial antigens prevents atherosclerosis in ApoE ^{â°'/â°'} mice. Cardiovascular Therapeutics, 2016, 34, 314-324.	2.5	4
4	Regulating Inflammatory Immune Response to Atherogenic Antigens Prevents Development and Progression of Atherosclerosis in New Zealand White Rabbits. Canadian Journal of Cardiology, 2016, 32, 1008.e1-1008.e10.	1.7	6
5	Modulation of Recombinant Antigenic Constructs Containing Multi-Epitopes towards Effective Reduction of Atherosclerotic Lesion in B6;129S-Ldlrtm1HerApobtm2Sgy/J Mice. PLoS ONE, 2015, 10, e0123393.	2.5	4
6	Oral dosing with multi-antigenic construct induces atheroprotective immune tolerance to individual peptides in mice. International Journal of Cardiology, 2014, 175, 340-351.	1.7	17
7	Impact of Matrix Metalloproteinases on Atherosclerosis. Current Drug Targets, 2014, 15, 442-453.	2.1	45
8	Activation of inflammatory cells and cytokines by peptide epitopes in vitro: a simple in-vitro screening assay for prioritizing them for in-vivo studies. Inflammation Research, 2013, 62, 471-481.	4.0	5
9	Comparison of Oral Tolerance to ApoB and HSP60 Peptides in Preventing Atherosclerosis Lesion Formation in Apob48â^'/Ldlrâ^' Mice. Journal of Vaccines, 2013, 2013, 1-13.	0.6	2
10	Mucosal Tolerance to a Combination of ApoB and HSP60 Peptides Controls Plaque Progression and Stabilizes Vulnerable Plaque in Apobtm2SgyLdlrtm1Her/J Mice. PLoS ONE, 2013, 8, e58364.	2.5	27
11	Immunization of Chlamydia pneumoniae (Cpn)-Infected Apobtm2SgyLdlrtm1Her/J Mice with a Combined Peptide of Cpn Significantly Reduces Atherosclerotic Lesion Development. PLoS ONE, 2013, 8, e81056.	2.5	4
12	Immunization With a Combination of 2 Peptides Derived From the C5a Receptor Significantly Reduces Early Atherosclerotic Lesion in <i>Ldlr</i> ^{<i>tm1Her</i>} <i>Apob</i> ^{<i>tm2Sgy</i>} J Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2358-2371.	2.4	16
13	Impact of multiple antigenic epitopes from ApoB100, hHSP60 and Chlamydophila pneumoniae on atherosclerotic lesion development in Apobtm2SgyLdlrtm1Her J mice. Atherosclerosis, 2012, 225, 56-68.	0.8	20
14	ADAM-15 Disintegrin-Like Domain Structure and Function. Toxins, 2010, 2, 2411-2427.	3.4	12
15	Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early atherosclerotic lesion in Apobtm2SgyLdlrtm1Her/J mice. Atherosclerosis, 2010, 212, 472-480.	0.8	40
16	ADAM Proteins- Therapeutic Potential in Cancer. Current Cancer Drug Targets, 2008, 8, 720-732.	1.6	37
17	The Effect of the Single Substitution of Arginine within the RGD Tripeptide Motif of a Modified Neurotoxin Dendroaspin on Its Activity of Platelet Aggregation and Cell Adhesion. Cell Communication and Adhesion, 2006, 13, 171-183.	1.0	14
18	Arg-Tyr-Asp (RYD) and Arg-Cys-Asp (RCD) motifs in dendroaspin promote selective inhibition of β1 and β3 integrins. Biochemical Journal, 2001, 356, 11.	3.7	8

Xinjie Lu

#	Article	IF	CITATIONS
19	Evaluation of the role of proline residues flanking the RGD motif of dendroaspin, an inhibitior of platelet aggregation and cell adhesion. Biochemical Journal, 2001, 355, 633-638.	3.7	16
20	Substitutions of Proline 42 to Alanine and Methionine 46 to Asparagine around the RGD Domain of the Neurotoxin Dendroaspin Alter Its Preferential Antagonism to That Resembling the Disintegrin Elegantin. Journal of Biological Chemistry, 1996, 271, 289-294.	3.4	36
21	Threeâ€dimensional structure of the RGDâ€containing snake toxin albolabrin in solution, based on ¹ H NMR spectroscopy and simulated annealing calculations. International Journal of Peptide and Protein Research, 1996, 48, 220-228.	0.1	43
22	Three-dimensional structure of the RGD-containing neurotoxin homologue dendroaspin. Nature Structural Biology, 1994, 1, 802-807.	9.7	47
23	1H-NMR Assignments and Secondary Structure of Dendroaspin, an RGD-Containing Glycoprotein IIb-IIIa (alphallb-beta3) Antagonist with a Neurotoxin Fold. FEBS Journal, 1994, 226, 861-868.	0.2	13
24	1H-NMR studies and secondary structure of the RGD-containing snake toxin, albolabrin. FEBS Journal, 1993, 218, 853-860.	0.2	13
25	Dendroaspin: A potent integrin receptor inhibitor from the venoms of <i>Dendroaspis viridis</i> and <i>D. jamesonii</i> . Biochemical Society Transactions, 1993, 21, 73S-73S.	3.4	30